[
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript",
    "summary": "Biogen Inc. (BIIB) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...",
    "url": "https://finnhub.io/api/news?id=70f25809e9c770b4f4fde78b9afc3a9b59d55fc18802c48cccc576829a7625f9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761858990,
      "headline": "Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript",
      "id": 137273129,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Biogen Inc. (BIIB) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...",
      "url": "https://finnhub.io/api/news?id=70f25809e9c770b4f4fde78b9afc3a9b59d55fc18802c48cccc576829a7625f9"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc (BIIB) Q3 2025 Earnings Call Highlights: Strong Product Launch Growth and Strategic ...",
    "summary": "Biogen Inc (BIIB) reports robust financial performance with significant growth in launch products and a focus on expanding its pipeline for future success.",
    "url": "https://finnhub.io/api/news?id=5b4f6ed0af6a306b6a47a7a51b37118a4c18671043be3ff9968c24e1d6b9d59e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761856022,
      "headline": "Biogen Inc (BIIB) Q3 2025 Earnings Call Highlights: Strong Product Launch Growth and Strategic ...",
      "id": 137275436,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc (BIIB) reports robust financial performance with significant growth in launch products and a focus on expanding its pipeline for future success.",
      "url": "https://finnhub.io/api/news?id=5b4f6ed0af6a306b6a47a7a51b37118a4c18671043be3ff9968c24e1d6b9d59e"
    }
  },
  {
    "ts": null,
    "headline": "Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem",
    "summary": "Two of Biogen's key growth drivers hit snags in the third-quarter. But Biogen stock yo-yoed and, most recently, edged down slightly.",
    "url": "https://finnhub.io/api/news?id=dbf8c4f8f3c06e303f73d7f80abbd41c7584020d2943576e261e5efade55afc7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761854801,
      "headline": "Biogen's Growth Drivers Hit Third-Quarter Snags; Why This Isn't A 'Fundamental' Problem",
      "id": 137269705,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Two of Biogen's key growth drivers hit snags in the third-quarter. But Biogen stock yo-yoed and, most recently, edged down slightly.",
      "url": "https://finnhub.io/api/news?id=dbf8c4f8f3c06e303f73d7f80abbd41c7584020d2943576e261e5efade55afc7"
    }
  },
  {
    "ts": null,
    "headline": "BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View",
    "summary": "Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.",
    "url": "https://finnhub.io/api/news?id=f19d74c8a97e266d792890e04ccfcc3a18f6d4714b7bb0119dbdc23958f7b0cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761847320,
      "headline": "BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View",
      "id": 137269706,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.",
      "url": "https://finnhub.io/api/news?id=f19d74c8a97e266d792890e04ccfcc3a18f6d4714b7bb0119dbdc23958f7b0cc"
    }
  },
  {
    "ts": null,
    "headline": "Why Wall Street’s Changing Outlook Is Shaping the Next Chapter for Biogen",
    "summary": "Biogen stock’s consensus analyst price target has ticked up slightly, moving from $172.34 to $172.55. This adjustment reflects fresh optimism around the company’s growth prospects, as well as nuanced shifts in both bullish and bearish analyst outlooks. Investors will want to follow closely to understand how changing views and upcoming catalysts could continue shaping Biogen’s story in the months ahead. Stay updated as the Fair Value for Biogen shifts by adding it to your watchlist or...",
    "url": "https://finnhub.io/api/news?id=29aa4d4072c430d1850a5666482696ce0a9a7f3574a1924b2cb3762d7136aa9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761844388,
      "headline": "Why Wall Street’s Changing Outlook Is Shaping the Next Chapter for Biogen",
      "id": 137269707,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen stock’s consensus analyst price target has ticked up slightly, moving from $172.34 to $172.55. This adjustment reflects fresh optimism around the company’s growth prospects, as well as nuanced shifts in both bullish and bearish analyst outlooks. Investors will want to follow closely to understand how changing views and upcoming catalysts could continue shaping Biogen’s story in the months ahead. Stay updated as the Fair Value for Biogen shifts by adding it to your watchlist or...",
      "url": "https://finnhub.io/api/news?id=29aa4d4072c430d1850a5666482696ce0a9a7f3574a1924b2cb3762d7136aa9a"
    }
  },
  {
    "ts": null,
    "headline": "Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win",
    "summary": "Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.",
    "url": "https://finnhub.io/api/news?id=0b7db40fdb24f96cfc1522576d238ff69d113c1cd783728c9e61141b9c70cde9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761844380,
      "headline": "Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win",
      "id": 137275177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.",
      "url": "https://finnhub.io/api/news?id=0b7db40fdb24f96cfc1522576d238ff69d113c1cd783728c9e61141b9c70cde9"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Falls After Trump-Xi Talks; Meta Plunges On Cost Worries (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index dropped Thursday after Trump-Xi talks. Meta stock plunged on earnings.",
    "url": "https://finnhub.io/api/news?id=f513d24ae33dcd2622e4b69e03bee9048aa3955978b3eb5667656dd19e49d9f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761832427,
      "headline": "Stock Market Today: Dow Falls After Trump-Xi Talks; Meta Plunges On Cost Worries (Live Coverage)",
      "id": 137266328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index dropped Thursday after Trump-Xi talks. Meta stock plunged on earnings.",
      "url": "https://finnhub.io/api/news?id=f513d24ae33dcd2622e4b69e03bee9048aa3955978b3eb5667656dd19e49d9f4"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "summary": "While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=b63e61680e8fc4a1b583cb227e680cafba5c448e60490a227827dfb1afc26f05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831008,
      "headline": "Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates",
      "id": 137269708,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=b63e61680e8fc4a1b583cb227e680cafba5c448e60490a227827dfb1afc26f05"
    }
  },
  {
    "ts": null,
    "headline": "Biogen (NASDAQ:BIIB) Beats Q3 Sales Expectations",
    "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=9bf989d25d09a4013794305c951cb0b48e72ea010948a533e75e7142614ddbfd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761828361,
      "headline": "Biogen (NASDAQ:BIIB) Beats Q3 Sales Expectations",
      "id": 137267106,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 2.8% year on year to $2.53 billion. Its non-GAAP profit of $4.81 per share was 23.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=9bf989d25d09a4013794305c951cb0b48e72ea010948a533e75e7142614ddbfd"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise",
    "summary": "Biogen cut its full-year adjusted-earnings expectations, though third-quarter profit rose on strength from its Alzheimer’s drug and rare-disease treatments.",
    "url": "https://finnhub.io/api/news?id=7e7320dfa3eb9e4aad57b8c29821fb1e9adefdc52273c6242c3febd70f4aa203",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761824400,
      "headline": "Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise",
      "id": 137267107,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen cut its full-year adjusted-earnings expectations, though third-quarter profit rose on strength from its Alzheimer’s drug and rare-disease treatments.",
      "url": "https://finnhub.io/api/news?id=7e7320dfa3eb9e4aad57b8c29821fb1e9adefdc52273c6242c3febd70f4aa203"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates",
    "summary": "Biogen (BIIB) delivered earnings and revenue surprises of +23.65% and +8.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=5328c0d0bc6733f0cd1857b7ca2caef663d1503faa2e56b83572d28e34bc175e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761822902,
      "headline": "Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates",
      "id": 137267108,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) delivered earnings and revenue surprises of +23.65% and +8.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=5328c0d0bc6733f0cd1857b7ca2caef663d1503faa2e56b83572d28e34bc175e"
    }
  },
  {
    "ts": null,
    "headline": "Biogen shares slide as guidance cut overshadows Q3 earnings beat",
    "summary": "Investing.com -- Biogen Inc. (NASDAQ:BIIB) shares fell 2.6% after the biotech company cut its full-year earnings guidance despite reporting better-than-expected third quarter results, with adjusted earnings and revenue surpassing analyst estimates.",
    "url": "https://finnhub.io/api/news?id=201bdef8589e39003052ae69476643e7fe9cd135f16f0134c48f4277f5d2a89b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761821873,
      "headline": "Biogen shares slide as guidance cut overshadows Q3 earnings beat",
      "id": 137267109,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Investing.com -- Biogen Inc. (NASDAQ:BIIB) shares fell 2.6% after the biotech company cut its full-year earnings guidance despite reporting better-than-expected third quarter results, with adjusted earnings and revenue surpassing analyst estimates.",
      "url": "https://finnhub.io/api/news?id=201bdef8589e39003052ae69476643e7fe9cd135f16f0134c48f4277f5d2a89b"
    }
  },
  {
    "ts": null,
    "headline": "Sales of Leqembi® totaled 18 billion yen in the third quarter 2025",
    "summary": "BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 18 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 117.2 million which is an increase of approximately 68 percent compared to the royalty obtained by BioArctic for the third quarter 2024.",
    "url": "https://finnhub.io/api/news?id=ab472bc906763aaceb8989e0f968310b25ae4cc3a3bcea8a2f6b4397df5dd141",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761820380,
      "headline": "Sales of Leqembi® totaled 18 billion yen in the third quarter 2025",
      "id": 137267110,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BioArctic AB's (publ) (STO: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2025, in conjunction with their partner Biogen's third quarter report. In total, sales of JPY 18 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 117.2 million which is an increase of approximately 68 percent compared to the royalty obtained by BioArctic for the third quarter 2024.",
      "url": "https://finnhub.io/api/news?id=ab472bc906763aaceb8989e0f968310b25ae4cc3a3bcea8a2f6b4397df5dd141"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Inc. 2025 Q3 - Results - Earnings Call Presentation",
    "summary": "2025-10-30. The following slide deck was published by Biogen Inc.",
    "url": "https://finnhub.io/api/news?id=70dda5c9e05f49e2e0ad8c104e272636030adb4be2c9d7dba08974ab5201e25b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761814929,
      "headline": "Biogen Inc. 2025 Q3 - Results - Earnings Call Presentation",
      "id": 137266167,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "2025-10-30. The following slide deck was published by Biogen Inc.",
      "url": "https://finnhub.io/api/news?id=70dda5c9e05f49e2e0ad8c104e272636030adb4be2c9d7dba08974ab5201e25b"
    }
  },
  {
    "ts": null,
    "headline": "Biogen reports an 18% increase in adjusted quarterly EPS",
    "summary": "Biogen reported adjusted net income of $707.5m for Q3 2025, up 19% year-on-year. Adjusted EPS was $4.81, up 18% from $4.08 a year earlier.Revenue for the quarter was $2.53bn, exceeding expectations,...",
    "url": "https://finnhub.io/api/news?id=15b0d95a07b97b1a00eabe1941f802a0e0b2715f4ce5554495fed9020f62516e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761813150,
      "headline": "Biogen reports an 18% increase in adjusted quarterly EPS",
      "id": 137265934,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Biogen reported adjusted net income of $707.5m for Q3 2025, up 19% year-on-year. Adjusted EPS was $4.81, up 18% from $4.08 a year earlier.Revenue for the quarter was $2.53bn, exceeding expectations,...",
      "url": "https://finnhub.io/api/news?id=15b0d95a07b97b1a00eabe1941f802a0e0b2715f4ce5554495fed9020f62516e"
    }
  }
]